Exelixis
EXEL
#1680
Rank
$10.16 B
Marketcap
$35.61
Share price
2.24%
Change (1 day)
65.63%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : $0.68 Billion USD

According to Exelixis's latest financial reports the company's total liabilities are $0.68 Billion USD. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31$0.67 B16.36%
2022-12-31$0.58 B43.74%
2021-12-31$0.40 B57.08%
2020-12-31$0.25 B29.3%
2019-12-31$0.19 B48.11%
2018-12-31$0.13 B-63.59%
2017-12-31$0.37 B-26.87%
2016-12-31$0.50 B7.03%
2015-12-31$0.47 B8%
2014-12-31$0.43 B0.24%
2013-12-31$0.43 B2.92%
2012-12-31$0.42 B40.32%
2011-12-31$0.30 B-48.63%
2010-12-31$0.58 B16.17%
2009-12-31$0.50 B10.76%
2008-12-31$0.45 B40.19%
2007-12-31$0.32 B7.15%
2006-12-31$0.30 B10.67%
2005-12-31$0.27 B14.44%
2004-12-31$0.24 B22.6%
2003-12-31$0.19 B20.29%
2002-12-31$0.16 B49.18%
2001-12-31$0.10 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
$59.68 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
$60.84 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
$72.97 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
$76.47 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
$83.35 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
$108.12 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
$126.91 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
$51.1 M-92.54%๐Ÿ‡บ๐Ÿ‡ธ USA
$72.38 M-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA